WHO advises against remdesivir for coronavirus treatment

Latest News

WHO advises against remdesivir for coronavirus treatment

Thursday, November 19, 2020

Print this page Email A Friend!


PARIS,France(AFP)— The anti-viral drug remdesivir should not be used to treat COVID-19 patients no matter how severe their illness as it has "no important effect" on survival chances, the World Health Organization said Friday.

Scratching one of the few treatments that had shown some initial promise in severe patients, a WHO Guideline Development Group (GDG) of international experts said there was "no evidence based on currently available data that it does improve patient-important outcomes".

The United States, the European Union and other countries have granted temporary approval for the use of remdesivir after initial research showed it may shorten recovery time in some coronavirus patients.

President Donald Trump was treated with remdesivir among other medicines after he tested positive for COVID-19 in October.

Friday's WHO recommendation was based on four international randomised trials among more than 7,000 patients hospitalised with the virus.

Publishing updated treatment guidance in the BMJ medical journal, the panel acknowledged that their recommendation does not mean that remdesivir has no benefit for patients.

But based on the latest figures, costs and delivery methods, it advised "against administering remdesivir in addition to usual care for the treatment of patients hospitalised with COVID-19, regardless of disease severity".

Manufacturer Gilead said last month that the drug had boosted 2020 third quarter sales by almost US$900 million.

Initially developed as a treatment for the Ebola virus, remdesivir was found in one study published in May to reduce the length of hospital stays for COVID-19 sufferers from 15 to 11 days on average.

A subsequent WHO pre-print however found the drug "appeared to have little or no effect" on mortality or length of hospitalisation among more than 11,000 hospitalised patients across 30 countries.


Now you can read the Jamaica Observer ePaper anytime, anywhere. The Jamaica Observer ePaper is available to you at home or at work, and is the same edition as the printed copy available at http://bit.ly/epaper-login


ADVERTISEMENT




POST A COMMENT

HOUSE RULES

1. We welcome reader comments on the top stories of the day. Some comments may be republished on the website or in the newspaper � email addresses will not be published.

2. Please understand that comments are moderated and it is not always possible to publish all that have been submitted. We will, however, try to publish comments that are representative of all received.

3. We ask that comments are civil and free of libellous or hateful material. Also please stick to the topic under discussion.

4. Please do not write in block capitals since this makes your comment hard to read.

5. Please don't use the comments to advertise. However, our advertising department can be more than accommodating if emailed: advertising@jamaicaobserver.com.

6. If readers wish to report offensive comments, suggest a correction or share a story then please email: community@jamaicaobserver.com.

7. Lastly, read our Terms and Conditions and Privacy Policy



comments powered by Disqus
ADVERTISEMENT

Poll

ADVERTISEMENT
ADVERTISEMENT

Today's Cartoon

Click image to view full size editorial cartoon
ADVERTISEMENT